The global peptide therapeutic market is undergoing a seismic shift, driven by the explosive demand for metabolic peptides (GLP-1 analogues) and high-potency cosmetic actives. At ThinHeal, we bridge the gap between laboratory-scale synthesis and industrial commercialization.
Successful peptide manufacturing requires rigorous control over solid-phase peptide synthesis (SPPS). Our roadmap includes:
A: Depending on the sequence complexity and scale, R&D feasibility takes 1-2 weeks, with production campaigns ranging from 4-8 weeks.
A: Every batch undergoes rigorous COA testing, including HPLC, MS, and endotoxin checks, ensuring data transparency for our global partners.
Thin
